An almost constant stream of trial results for Aiirbs in additional indicationscan be expected over the period to 2006/7. If these trials are positive, salesof the Aiirbs will increase dramatically.Being better tolerated than older anti-hypertensives and potentially effectivethroughout the cardiovascular continuum, the Aiirbs look set to dominate theanti-hypertensives market.
